Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas

Journal of Clinical Oncology

Volumn 33, Issue 36, 2015, Pages 4276-4283

  Casali, Paolo G ^a   Le Cesne, Axel ^c   Velasco, Andres Poveda ^h   Kotasek, Dusan ^j   Rutkowski, Piotr ^m   Hohenberger, Peter ⁿ   Fumagalli, Elena ^a   Judson, Ian R ^p   Italiano, Antoine ^d   Gelderblom, Hans ^r   Adenis, Antoine ^e   Hartmann, Jörg T ^o   Duffaud, Florence ^f   Goldstein, David ^k   Broto, Javier M ⁱ   Gronchi, Alessandro ^a   Dei Tos, Angelo P ^b   Marréaud, Sandrine ^t   Van Der Graaf, Winette T A ^q,s   Zalcberg, John R ^l   Litière, Saskia ^t   Blay, Jean Yves ^g   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Rianimazione e Terapia Intensiva   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT BERGONIÉ   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g CENTRE LÉON BÉRARD   (France)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k PRINCE OF WALES HOSPITAL   (Australia)

^l PETER MACCALLUM CANCER CENTRE   (Australia)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o UNIVERSITY OF KIEL   (Germany)

^p Royal Marsden Hospital   (United Kingdom)

^q INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^s RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^t EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PATHOLOGIST; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURGICAL PATIENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; AGED; ANTAGONISTS AND INHIBITORS; AUSTRALIA AND NEW ZEALAND; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EUROPEAN UNION; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; INTERNATIONAL COOPERATION; KAPLAN MEIER METHOD; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; ODDS RATIO; PREVENTION AND CONTROL; PROCEDURES; SALVAGE THERAPY; TREATMENT FAILURE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALASIA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EUROPEAN UNION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMATINIB MESYLATE; INTERNATIONAL COOPERATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 84955571000     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.4304     Document Type: Article

References (18)

1. Nilsson B, Bumming P, Meis-Kindblom JM, et al: Gastrointestinal stromal tumors: The incidence, prevalence clinical course, and prognostication in the pre-imatinib mesylate era - A population based study in western Sweden. Cancer 103:821-829, 2005
2. Joensuu H, Hohenberger P, Corless CL: Gastrointestinal stromal tumor. Lancet 382:973-983, 2013
3. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 358:1421-1423, 2001
4. Blanke CD, Demetri GD, von Mehren M, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625, 2008
5. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
6. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008
7. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009
8. Joensuu H, Eriksson M, Sundby Hall K, et al: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307:1265-1272, 2012
9. Fletcher CDM, Bermann JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumor: A consensus approach. Hum Pathol 33:459-465, 2002
10. Miettinen M, Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83, 2006
11. Joensuu H, Vehtari A, Riihimäki J, et al: Risk of gastrointestinal stromal tumor recurrence after surgery: An analysis of pooled population-based cohorts. Lancet Oncol 13:265-274, 2012
12. Hohenberger P, Ronellenfitsch U, Oladeji O, et al: Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumor. Br J Surg 97:1854-1859, 2010
13. DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58, 2000
14. Corless CL, Ballman KV, Antonescu CR, et al: Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial. J Clin Oncol 32:1563-1570, 2014
15. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol 28:1247-1253, 2010
16. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
17. Demetri GD, Reichardt P, Kang YK, et al: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302, 2013
18. Demetri GD, Jeffers M, Reichardt P, et al: Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. J Clin Oncol 31:, 2013 (suppl; abstr 10503)